Cantor Fitzgerald Reiterates Overweight on ARS Pharmaceuticals, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on ARS Pharmaceuticals (NASDAQ:SPRY) and maintained a $30 price target.
September 16, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on ARS Pharmaceuticals, maintaining a $30 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a $30 price target by a reputable analyst suggests positive sentiment and potential upside for ARS Pharmaceuticals. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100